-

QT Imaging Holdings to Attend Radiological Society of North America 2024 Annual Meeting

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce participation at the Radiological Society of North America 2024 Annual Meeting, taking place in Chicago, December 1-5, 2024. Dr. Bilal Malik, Chief Science Officer, Dr. James Wiskin, Fellow, and Dr. Raluca Dinu, Chief Executive Officer, will represent QTI at the event.

Dr. Bilal Malik will deliver a presentation on December 4th during the 9:30 am session on Breast Ultrasound Techniques. His talk titled: “Assessing Non-inferiority of quantitative transmission (QT) ultrasound imaging compared with digital breast tomosynthesis (DBT): Results from multi-reader, multi-case (MRMC) observer study”, will highlight the comparative performance of QTI’s and DBT technologies in breast imaging, with an emphasis on findings from the MRMC study that support the potential of QTI as a reliable and effective alternative for breast cancer screening and diagnosis. “Our study represents a major milestone in breast imaging,” said Dr. Malik. “By demonstrating that QTI performs on par with DBT, we are opening the door to safe, more accessible, and patient-friendly diagnostic option.” Additional details will be shared during the presentation.

About QT Imaging Holding, Inc.

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Contacts

For media inquiries, please contact:
Susan Schaffler
Head of Communications
Susan.Schaffler@qtimaging.com

Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com

QT Imaging Holdings, Inc.

NASDAQ:QTI

Release Versions

Contacts

For media inquiries, please contact:
Susan Schaffler
Head of Communications
Susan.Schaffler@qtimaging.com

Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com

More News From QT Imaging Holdings, Inc.

QT Imaging Announces Shipping Forty Breast Acoustic CT™ Scanners in 2025 and Meeting Its Revenue Guidance

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025. “2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in...

QT Imaging Reports Strong Third Quarter 2025 Financial Results

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the three and nine months ended September 30, 2025, and provided a business update. “I am pleased to report that our team delivered another strong performance,” said Dr. Raluca Dinu, QT Imaging Chief Executive Officer. “This quarter’s res...

Accomplished Industry Veteran, Satrajit Misra, Joins QT Imaging as Chief Commercial Officer

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (OTCQB: QTIH), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce the appointment of Satrajit Misra as the Company’s Chief Commercial Officer (“CCO”). Mr. Misra’s appointment underscores QTI’s commitment to innovation, clinical excellence, and commercial execution in delivering accessible, radiation-free...
Back to Newsroom